Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Immunotherapeutic Approaches for Endometrial Cancer

Faculty

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology of Endometrial Cancer (EC); Rationale for the Use of Immune Checkpoint Inhibitors

• Historical role of and outcomes achieved with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
• Similarities and differences among the currently available anti-PD-1/PD-L1 antibodies for EC, such as dostarlimab, pembrolizumab and durvalumab
• Biological rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with EC
• Frequency of potential biomarkers of response to immune checkpoint inhibitors in EC (eg, microsatellite instability [MSI]/mismatch repair [MMR] deficiency, POLE mutations); optimal approach to biomarker assessment for patients with newly diagnosed disease

MODULE 2: First-Line Therapy for Advanced or Recurrent EC

• Key efficacy findings with dostarlimab, pembrolizumab and durvalumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
• Impact of MSI/MMR status on outcomes with the addition of anti-PD-1/PD-L1 antibodies to chemotherapy
• FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MSI/MMR status and of durvalumab in combination with chemotherapy for those with MMR-deficient disease
• Optimal incorporation of anti-PD-1/PD-L1 antibodies into up-front therapy for patients with advanced or recurrent EC

MODULE 3: Potential Benefits of PARP Inhibition Combined with Immunotherapy for Advanced EC

• Mechanism of antitumor activity of PARP inhibitors and biological rationale for their investigation in EC; potential therapeutic synergy between PARP inhibitors and immune checkpoint inhibitors
• Benefits observed with first-line dostarlimab and carboplatin/paclitaxel followed by dostarlimab/niraparib maintenance compared to carboplatin/paclitaxel alone in advanced or recurrent EC
• Published efficacy and safety results with durvalumab in combination with chemotherapy followed by durvalumab and olaparib maintenance for patients with newly diagnosed advanced or recurrent EC
• Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the care of patients with EC

MODULE 4: Tolerability and Other Practical Considerations with Anti-PD-1/PD-L1 Antibodies for Previously Untreated Advanced EC

• Pathophysiology, incidence and spectrum of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies in advanced EC
• Recommended monitoring and management approaches for immune-related and other AEs with immune checkpoint inhibitors
• Strategies to discern whether toxicities stem from anti-PD-1/PD-L1 antibodies or their therapeutic partners (eg, chemotherapy, PARP inhibitors) when these agents are administered in combination
• Role of rechallenge in treatment for patients for whom immune checkpoint inhibitor therapy has been held due to immune-mediated toxicity
• Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, in treatment for patients with preexisting autoimmune conditions or a history of solid organ transplant

MODULE 5: Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC

• Biological rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
• Long-term findings, including overall survival data, supporting the use of lenvatinib in combination with pembrolizumab for patients with MMR-proficient advanced EC with disease progression after prior systemic therapy
• Optimal integration of lenvatinib/pembrolizumab into EC management algorithms
• Utility of lenvatinib/pembrolizumab among patients who have experienced disease progression on up-front chemoimmunotherapy

MODULE 6: Toxicities with Lenvatinib/Pembrolizumab

• Incidence, severity, timing and management of AEs observed in patients with EC receiving lenvatinib/pembrolizumab (eg, hypertension, gastrointestinal issues, weight loss, hand-foot syndrome)
• Approaches to encourage adequate nutrition among patients receiving the combination of lenvatinib and pembrolizumab
• Initial dosing and dose-modification strategies for lenvatinib/pembrolizumab in EC; available data exploring the impact of lenvatinib dose reductions on antitumor activity
• Strategies to determine the cause of toxicities that could stem from either lenvatinib or pembrolizumab among patients receiving the combination

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer (EC).
• Appreciate available clinical research findings with the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC, and reflect upon the potential role of this novel strategy.
• Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and counsel patients with metastatic EC about the risks and benefits of this approach.
• Appreciate the side effects associated with various systemic therapies commonly employed in the treatment of EC, and use this information to develop supportive management plans for patients undergoing treatment with these agents/regimens.
• Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/EndometrialCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Shaver and Dr Rauh-Hain have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Karpen — Speakers Bureaus: Amgen Inc.

MODERATOR — Dr Chase — Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Merck; Consulting Agreements: AbbVie Inc, GSK; Contracted Research: GSK, Merck; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Pfizer Inc; Nonrelevant Financial Relationships: NRG Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.